Thyroid Transcription Factor FOXE1 Interacts with ETS Factor ELK1 to Co-regulate TERT

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Nov 17

PMID 27852061

Citations 12

Authors

Martyn Bullock

Grace Lim

Cheng Li

In Ho Choi

Shivansh Kochhar

Chris Liddle

Lei Zhang

Roderick J Clifton-Bligh

Affiliations

Soon will be listed here.

Abstract

Background: Although FOXE1 was initially recognized for its role in thyroid organogenesis, more recently a strong association has been identified between the FOXE1 locus and thyroid cancer. The role of FOXE1 in adult thyroid, and in particular regarding cancer risk, has not been well established. We hypothesised that discovering key FOXE1 transcriptional partners would in turn identify regulatory pathways relevant to its role in oncogenesis.

Results: In a transcription factor-binding array, ELK1 was identified to bind FOXE1. We confirmed this physical association in heterologously transfected cells by IP and mammalian two-hybrid assays. In thyroid tissue, endogenous FOXE1 was shown to bind ELK1, and using ChIP assays these factors bound thyroid-relevant gene promoters TPO and TERT in close proximity to each other. Using a combination of electromobility shift assays, TERT promoter assays and siRNA-silencing, we found that FOXE1 positively regulated TERT expression in a manner dependent upon its association with ELK1. Treating heterologously transfected thyroid cells with MEK inhibitor U0126 inhibited FOXE1-ELK1 interaction, and reduced TERT and TPO promoter activity.

Methodology: We investigated FOXE1 interactions within in vitro thyroid cell models and human thyroid tissue using a combination of immunoprecipitation (IP), chromatin IP (ChIP) and gene reporter assays.

Conclusions: FOXE1 interacts with ELK1 on thyroid relevant gene promoters, establishing a new regulatory pathway for its role in adult thyroid function. Co-regulation of TERT suggests a mechanism by which allelic variants in/near FOXE1 are associated with thyroid cancer risk.

Citing Articles

BRAF-induced EHF Expression Affects TERT in Aggressive Papillary Thyroid Cancer.

Xu Y, Gao J, Wang N, Zedenius J, Nilsson I, Lui W J Clin Endocrinol Metab. 2024; 110(3):693-705.

PMID: 39183149 PMC: 11834717. DOI: 10.1210/clinem/dgae589.

Transcription factor roles in the local adaptation to temperature in the Andean Spiny Toad Rhinella spinulosa.

Hinostroza F, Araya-Duran I, Pineiro A, Lobos I, Pastenes L Sci Rep. 2024; 14(1):15158.

PMID: 38956427 PMC: 11220030. DOI: 10.1038/s41598-024-66127-5.

Validation of human telomere length multi-ancestry meta-analysis association signals identifies POP5 and KBTBD6 as human telomere length regulation genes.

Keener R, Chhetri S, Connelly C, Taub M, Conomos M, Weinstock J Nat Commun. 2024; 15(1):4417.

PMID: 38789417 PMC: 11126610. DOI: 10.1038/s41467-024-48394-y.

InTERTwined: how promoter mutations impact BRAF-driven thyroid cancers.

Landa I Curr Opin Endocr Metab Res. 2023; 30.

PMID: 37576936 PMC: 10419322. DOI: 10.1016/j.coemr.2023.100460.

Multiple ETS Factors Participate in the Transcriptional Control of Mutant Promoter in Thyroid Cancers.

Thornton C, Hao J, Tamarapu P, Landa I Cancers (Basel). 2022; 14(2).

PMID: 35053525 PMC: 8774187. DOI: 10.3390/cancers14020357.

References

Carlsson P, Mahlapuu M . Forkhead transcription factors: key players in development and metabolism. Dev Biol. 2002; 250(1):1-23. DOI: 10.1006/dbio.2002.0780. View

Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H . Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008; 14(5):518-27. DOI: 10.1038/nm1764. View

Chen Y, Ruben E, Rajadas J, Teng N . In silico investigation of FOXM1 binding and novel inhibitors in epithelial ovarian cancer. Bioorg Med Chem. 2015; 23(15):4576-4582. DOI: 10.1016/j.bmc.2015.06.002. View

Castanet M, Park S, Smith A, Bost M, Leger J, Lyonnet S . A novel loss-of-function mutation in TTF-2 is associated with congenital hypothyroidism, thyroid agenesis and cleft palate. Hum Mol Genet. 2002; 11(17):2051-9. DOI: 10.1093/hmg/11.17.2051. View

Castanet M, Mallya U, Agostini M, Schoenmakers E, Mitchell C, Demuth S . Maternal isodisomy for chromosome 9 causing homozygosity for a novel FOXE1 mutation in syndromic congenital hypothyroidism. J Clin Endocrinol Metab. 2010; 95(8):4031-6. DOI: 10.1210/jc.2010-0275. View

Carre A, Hamza R, Kariyawasam D, Guillot L, Teissier R, Tron E . A novel FOXE1 mutation (R73S) in Bamforth-Lazarus syndrome causing increased thyroidal gene expression. Thyroid. 2013; 24(4):649-54. PMC: 3993030. DOI: 10.1089/thy.2013.0417. View

Johnson D, Mortazavi A, Myers R, Wold B . Genome-wide mapping of in vivo protein-DNA interactions. Science. 2007; 316(5830):1497-502. DOI: 10.1126/science.1141319. View

Liu R, Xing M . TERT promoter mutations in thyroid cancer. Endocr Relat Cancer. 2016; 23(3):R143-55. PMC: 4750651. DOI: 10.1530/ERC-15-0533. View

Weinhold N, Jacobsen A, Schultz N, Sander C, Lee W . Genome-wide analysis of noncoding regulatory mutations in cancer. Nat Genet. 2014; 46(11):1160-5. PMC: 4217527. DOI: 10.1038/ng.3101. View

10.

Katoh M, Igarashi M, Fukuda H, Nakagama H, Katoh M . Cancer genetics and genomics of human FOX family genes. Cancer Lett. 2012; 328(2):198-206. DOI: 10.1016/j.canlet.2012.09.017. View

11.

Selvaraj N, Kedage V, Hollenhorst P . Comparison of MAPK specificity across the ETS transcription factor family identifies a high-affinity ERK interaction required for ERG function in prostate cells. Cell Commun Signal. 2015; 13:12. PMC: 4338625. DOI: 10.1186/s12964-015-0089-7. View

12.

De Val S, Chi N, Meadows S, Minovitsky S, Anderson J, Harris I . Combinatorial regulation of endothelial gene expression by ets and forkhead transcription factors. Cell. 2008; 135(6):1053-64. PMC: 2782666. DOI: 10.1016/j.cell.2008.10.049. View

13.

Kallel R, Belguith-Maalej S, Akdi A, Mnif M, Charfeddine I, Galofre P . Genetic investigation of FOXE1 polyalanine tract in thyroid diseases: new insight on the role of FOXE1 in thyroid carcinoma. Cancer Biomark. 2011; 8(1):43-51. DOI: 10.3233/DMA-2011-0824. View

14.

Nonaka D, Tang Y, Chiriboga L, Rivera M, Ghossein R . Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol. 2007; 21(2):192-200. DOI: 10.1038/modpathol.3801002. View

15.

Messeguer X, Escudero R, Farre D, Nunez O, Martinez J, Alba M . PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics. 2002; 18(2):333-4. DOI: 10.1093/bioinformatics/18.2.333. View

16.

Vallarelli A, Rachakonda P, Andre J, Heidenreich B, Riffaud L, Bensussan A . TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation. Oncotarget. 2016; 7(33):53127-53136. PMC: 5288173. DOI: 10.18632/oncotarget.10634. View

17.

Nakagawa S, Gisselbrecht S, Rogers J, Hartl D, Bulyk M . DNA-binding specificity changes in the evolution of forkhead transcription factors. Proc Natl Acad Sci U S A. 2013; 110(30):12349-54. PMC: 3725104. DOI: 10.1073/pnas.1310430110. View

18.

Bychkov A, Saenko V, Nakashima M, Mitsutake N, Rogounovitch T, Nikitski A . Patterns of FOXE1 expression in papillary thyroid carcinoma by immunohistochemistry. Thyroid. 2013; 23(7):817-28. PMC: 3704107. DOI: 10.1089/thy.2012.0466. View

19.

Gudmundsson J, Sulem P, Gudbjartsson D, Jonasson J, Sigurdsson A, Bergthorsson J . Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat Genet. 2009; 41(4):460-4. PMC: 3664837. DOI: 10.1038/ng.339. View

20.

Ortiz L, Aza-Blanc P, Zannini M, Cato A, Santisteban P . The interaction between the forkhead thyroid transcription factor TTF-2 and the constitutive factor CTF/NF-1 is required for efficient hormonal regulation of the thyroperoxidase gene transcription. J Biol Chem. 1999; 274(21):15213-21. DOI: 10.1074/jbc.274.21.15213. View